The contribution of the intestinal permeability in the systemic inflammation in patients with COPD during acute exercise
- Conditions
- COPD10024967
- Registration Number
- NL-OMON33923
- Lead Sponsor
- niversiteit Maastricht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 105
Diagnosis of COPD, both male and female, age-range from 50 to 70 years, no respiratory tract infection or exacerbation of the disease for at least 4 weeks before the study, capable to provide informed consent, presence of other non-gastro-intestinal related, non-cardiovascular and non-renal chronic diseases are allowed in case the clinical status is stable for at least 4 weeks before the study;
External oxygen supplementation at rest; investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements; participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study; any kind of gastro-intestinal complains or gastrointestinal disease; use of NSAID (ibuprofen, acetylsalicic acid, naproxen, meloxicam, diclofenac); subjects who are still smoking as smoking is known to increase the intestinal permeability.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Biochemical parameters: markers of intestinal permeability in plasma<br /><br>(intestinal fatty acid binding protein (IFABP), ileal lipid-binding protein<br /><br>(ILBP), claudine) and urine (sugars)</p><br>
- Secondary Outcome Measures
Name Time Method <p>Plasma markers of systemic inflammation interleukine 6 (IL-6), tumor necrosis<br /><br>factor-a (TNF-a), TNF soluble receptors 55 en 75, C-reactive protein (CRP),<br /><br>lipoprotein binding protein (LBP) and chemotactic cytokine ligand 18 (CCL-18).</p><br>